How Does Cannabis Affect Hunger, and What Role Does It Play for Cancer Patients?

THC can increase hunger and short-term food intake, an effect often called “the munchies.” That effect helps explain interest in cannabis for appetite loss, but it does not establish that cannabis prevents or reverses cancer cachexia—the wasting syndrome that can involve loss of muscle and body weight.

For someone with cancer, the useful question is whether a treatment improves eating, nutrition, function, and comfort without unacceptable side effects. Feeling hungrier for a short period is only one possible part of that assessment.

How Cannabis Influences Hunger

The endocannabinoid system participates in appetite regulation. THC acts at cannabinoid receptors, including CB1 receptors in brain circuits involved in feeding and reward. The resulting effects involve several interacting pathways rather than a single universal “hunger hormone” switch.

In a 2015 mouse study, activating CB1 receptors increased feeding through a surprising role for hypothalamic POMC neurons, which are usually associated with satiety. The experiments implicated increased release of beta-endorphin. This was a mechanistic animal finding, not a trial showing that cannabis treats appetite loss in cancer patients.

A Washington State University study published in December 2023 used both rats and mice. Cannabis vapor increased meal frequency and food-seeking behavior, while optical imaging and other experiments identified a role for hunger-related hypothalamic neurons, including AgRP neurons. These findings clarify biological mechanisms but do not determine a safe or effective cancer-treatment regimen.

What Newer Human Research Adds

A 2025 study combining human and rat experiments found that vaporized cannabis increased short-term energy intake. In the human experiment, the increase occurred during the first 30 minutes of access to snacks and beverages. The proportions of carbohydrate, fat, and protein consumed did not change.

This supports an acute effect on eating. It does not show sustained weight gain, preservation of muscle, or improved outcomes in people with cancer cachexia. Results from a controlled vapor experiment also cannot be assumed to apply equally to every edible, oil, strain, or dose.

Appetite Loss and Cancer Cachexia Are Different

Appetite loss can result from nausea, pain, mouth sores, swallowing problems, altered taste, medications, and other effects of cancer or its treatment. Identifying the cause helps the care team select an appropriate intervention.

As the National Cancer Institute’s nutrition summary explains, cancer cachexia can occur even when calorie and protein intake are adequate because tumor-related processes interfere with maintaining muscle and fat. Stimulating appetite alone may therefore be insufficient.

Clinical results for cannabinoids in this setting have been disappointing. NCI describes a trial of 469 patients in which dronabinol was less effective than megestrol acetate, with no additional benefit from combining them. It also describes a 243-patient trial that did not demonstrate benefit over placebo. These results do not justify saying cannabis prevents wasting syndrome.

Nutrition assessment, treatment of symptoms that interfere with eating, and ongoing monitoring of weight and strength are more informative than hunger alone. An oncology dietitian can help tailor food and nutrition support to the person’s circumstances.

Where Cannabinoid Medicines May Have a Role

Nausea and vomiting caused by chemotherapy are a separate indication. The NCI cannabis evidence summary notes that dronabinol and nabilone are FDA-approved for chemotherapy-related nausea and vomiting when conventional anti-nausea treatment has not worked adequately. Their defined formulations and prescribing instructions distinguish them from dispensary cannabis.

This does not make whole-plant cannabis preferable to prescribed treatment. Nor does symptom relief mean a product treats the cancer itself. The oncology team should review persistent nausea and other symptoms before a patient adds or substitutes a cannabinoid product.

Some patients also seek cannabis for pain, as discussed in our guide to reasons people use medical cannabis. A reason for use is not proof of effectiveness for an individual cancer patient, and pain management needs its own assessment.

Risks and Decisions to Discuss With the Care Team

THC can cause intoxication, impaired attention, dizziness, anxiety, and other adverse effects. Cannabinoids can also interact with medicines. NCI highlights concerns about interactions with some cancer therapies and the limitations of the available evidence. These issues matter when someone is already weak, taking sedating medicines, or receiving complex treatment.

There is no established basis for recommending a high-CBG strain as a proven alternative appetite treatment for cancer, or for selecting a strain solely by claims about CBD or THCV. Product names and cannabinoid percentages do not establish clinical benefit.

Before considering cannabis, discuss:

• What is preventing adequate eating and whether that cause can be treated directly.
• Whether weight or muscle loss is continuing, even when appetite improves.
• Which nutrition, medication, and supportive-care options fit the treatment plan.
• Potential interactions, adverse effects, and how any proposed benefit would be measured.

Report continuing weight loss, difficulty swallowing, persistent vomiting, or inability to maintain fluids promptly. Cannabis may change hunger, but it should not delay assessment or replace cancer care and nutrition support.